Clinical Trials Logo

Filter by:
NCT ID: NCT00713375 Recruiting - Clinical trials for Subarachnoid Hemorrhage

Time Frequency Analysis of Electrocardiogram and Blood Pressure in Intracranial Hemorrhage Patients

Start date: April 2008
Phase: N/A
Study type: Observational

Dysregulation of autonomic nervous system is evident in patients with spontaneous intracranial hemorrhage. In this study, we utilize a non-invasive method (heart rate and blood pressure variability analysis to analyze the autonomic activities in this group of neurosurgical patients. Our aim is to determine the utility of this modality in risk stratification and outcome prediction in these patients.

NCT ID: NCT00714077 Recruiting - Rectal Neoplasms Clinical Trials

Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer

Start date: April 2008
Phase: Phase 3
Study type: Observational

The purpose of this study is: - To compare the long-term of survival and local/regional control between the two postoperative concurrent chemoradiotherapy regimens: capecitabine vs. oxaliplatin and capecitabine,for stage II and III rectal cancer - To compare the toxicity profile between the two different concurrent chemoradiotherapy regimens.

NCT ID: NCT00715819 Recruiting - Pilomatrixoma Clinical Trials

Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma

Start date: April 2008
Phase: N/A
Study type: Observational

Stanford University Dermatology Clinics and Lucile Packard Children's Hospital are evaluating the use of the otoscope for the diagnosis of skin lesions. We are particularly looking for children and/or adults with nodules, cysts, tumors, or pilomatricomas. The study will take 15-30 minutes and we will use light to examine and take a picture of your skin lesion. There is no monetary compensation for participating in the study.

NCT ID: NCT00722930 Recruiting - Follicular Lymphoma Clinical Trials

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma

GOTEL-FL1LC
Start date: April 2008
Phase: Phase 2
Study type: Interventional

To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy

NCT ID: NCT00731809 Recruiting - Crohn's Disease Clinical Trials

Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Start date: April 2008
Phase: Phase 4
Study type: Interventional

18F-FDG PET/CT (2-[fluorine-18] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.

NCT ID: NCT00732511 Recruiting - Hypertension Clinical Trials

Coreg CR, Blood Vessel Stiffness and Blood Vessel Function

Start date: April 2008
Phase: Phase 4
Study type: Interventional

We are comparing the blood pressure-lowering effects of two marketed medications, Coreg CR and Toprol XL. Although both drugs reduce blood pressure by blocking the action of noradrenaline on beta-receptors in the blood vessels, Coreg CR also blocks alpha-receptors, which may provide added blood pressure-lowering. In addition, Coreg CR may have anti-oxidant actions. Cells which line blood vessels (termed "endothelial cells") make nitric oxide (NO), which relaxes the muscle cells encircling the blood vessels, causing a reduction in blood pressure. When body cells use oxygen, they normally produce "free radicals", which can destroy NO,leading to high blood pressure, heart damage and worsenimg of diabetes. Antioxidants remove free radicals and prevent or repair this damage. In this study we will measure endothelial cell function, blood vessel wall stiffness, NO in exhaled breath, and blood levels of substances which reflect NO production and destruction to determine if a pure beta-blocker (Toprol XL) differs from an alpha/beta blocker (Coreg CR) in these effects. We will also examine the mechanism by which such differences might occur.

NCT ID: NCT00734123 Recruiting - Clinical trials for Cardiovascular Diseases

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

PRIMARIA
Start date: April 2008
Phase: Phase 4
Study type: Interventional

The incidence of cardiovascular diseases is still high and further efforts should be done in primary prevention. The main objective is to quantify the burden of subclinical atherosclerosis using non-invasive techniques,and to study the impact of this assessment and consequent treatment in the progression of atherosclerosis and in the incidence of cardiovascular diseases.

NCT ID: NCT00738933 Recruiting - Atherosclerosis Clinical Trials

Dietary Phytosterols and Human Aortic Valve

Start date: April 2008
Phase: N/A
Study type: Interventional

This randomized controlled double-blind intervention study unravels influence of dietary plant sterols and stanols on the structure and the sterol composition of the human aortic valve. The study patients will include 50-60 voluntary patients from the Helsinki Univ. Central Hospital, who will undergo aortic valve surgery. The patients will be randomized into plant sterol (E), plant stanol (A) and control (C) groups. Patients in the E and A groups will be asked to consume daily 2 grams plant sterols or plant stanols, respectively, in a margarine product.

NCT ID: NCT00745394 Recruiting - Clinical trials for Cardiopulmonary Bypass

Validation of Near Infrared Spectroscopy (NIRS) During Heart-Lung Bypass in Children

NIRS
Start date: April 2008
Phase: N/A
Study type: Observational

Non-invasive assessment of blood flow to organs has long challenged clinicians. Recently, near infrared spectroscopy (NIRS) has been recognized as a methodology that may achieve this goal. A commercially available NIRS monitor, marketed by Somanetics, Inc., is now in widespread use in the clinical care of pediatric cardiac patients in the operating room and in the intensive care unit post-operatively. When a patch/probe from the monitor is placed on the forehead or lower back, blood oxygen concentration data is obtained which has been found to correlate with actual blood samples taken by IV. The presence of this NIRS data would give the surgeon important feedback about blood flow to important areas like the brain and kidneys during heart surgeries on children and after the operation is completed in the intensive care unit. The investigator wishes to perform a prospective study of the NIRS monitor use with children that need heart surgeries that require heart-lung bypass and sometimes require monitoring in the ICU, post-operatively.

NCT ID: NCT00747877 Recruiting - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Start date: April 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and bortezomib. It is not yet known whether high-dose melphalan given together with a second stem cell transplant is more effective than low-dose cyclophosphamide in treating patients with relapsed multiple myeloma. PURPOSE: This randomized phase III trial is studying giving high-dose melphalan together with a second stem cell transplant to see how well it works compared with low-dose cyclophosphamide in treating patients with relapsed multiple myeloma after chemotherapy.